LXRX Lexicon Pharmaceuticals, Inc. - Common Stock
$2,45
Preço · Ago 19, 2026
Fundamentais a partir de Ago 6, 2026
Intervalo 52 Semanas
$1–$3
86% of range
Classificação do Analista
BUY
11 analysts
Preço-Alvo
$4
+58% upside
P/E (TTM)
-17.5
ROE
-39.7%
Margem de Lucro Líquido
-101.1%
Sobre Lexicon Pharmaceuticals, Inc. - Common Stock Visão geral da empresa da Wikipedia
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Ler mais
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.
Company history
Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.
The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.
In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.
Technology
Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.
The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.
In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of diffrent compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.
Locations
Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.
Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.
== References ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
LXRX Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$2.44
Capitalização de Mercado
$894M
P/E (TTM)
-17.5
EPS (TTM)
$-0.14
Receita (TTM)
$50M
Rendimento div.
—
ROE
-39.7%
Dívida/Capital
0.5
Intervalo 52 Semanas
$1 – $3
LXRX Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$50M
2016-12-31
→
2025-12-31
EPS
$-0.14
2017-12-31
→
2025-12-31
Fluxo de caixa livre
$-68M
2016-12-31
→
2025-12-31
Margens
-101.1%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
LXRX
Mediana de Pares
P/E (TTM)
-17.5
29.9
P/S (TTM)
18.0
14.4
P/B
8.3
4.4
EV / EBITDA
-17.6
—
Price / FCF (Preço / FCF)
-13.2
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
LXRX
Mediana de Pares
Operating Margin (Margem Operacional)
-98.2%
—
Net Profit Margin (Margem de Lucro Líquido)
-101.1%
0.70%
ROA
-20.8%
-0.55%
ROE
-39.7%
-2.5%
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
LXRX
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
0.5
—
Current Ratio (Índice de liquidez corrente)
4.9
3.9
Quick Ratio (Índice de Liquidez Seca)
4.7
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
LXRX
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
60.2%
—
Revenue CAGR 3Y (CAGR Receita 3A)
610.2%
—
Revenue CAGR 5Y (CAGR Receita 5A)
15.7%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
LXRX
Mediana de Pares
LXRX Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
11 analistas
- Compra forte 3 27,3%
- Compra 5 45,5%
- Manter 3 27,3%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
5 analistas · 2026-08-19
Mediana
$3.10
Média
$3.86
Agora
$2.44
Mín
$2.00
Máx
$6.00
Alvo mediano
$3.10
+26,8%
Alvo médio
$3.86
+57,7%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.03%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $-0.07 | $-0.05 | -0.02% |
| 31 de Março de 2026 | $0.00 | $-0.04 | 0.04% |
| 31 de Dezembro de 2025 | $-0.04 | $-0.07 | 0.03% |
| 30 de Setembro de 2025 | $-0.04 | $-0.07 | 0.03% |
| 30 de Junho de 2025 | $0.01 | $-0.08 | 0.09% |
| 31 de Março de 2025 | $-0.07 | $-0.10 | 0.03% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | — |
| OMER | $1.23B | -343.6 | — | — | 1.9% | — |
| SPTX | — | — | — | — | — | — |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | — |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | — |
| SGP | — | — | — | — | 50.0% | — |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $2M | $3M | $2M | $2M | $0 | $0 | · | |
| R&D Expense | $61M | $84M | $59M | $53M | $55M | $154M | $92M | $100M | $152M | $164M | $95M | $89M | |
| SG&A Expense | $37M | $143M | $114M | $48M | $32M | $47M | $57M | $64M | $66M | $43M | $24M | $19M | |
| Operating Expenses | $99M | $228M | $173M | $101M | $87M | $204M | $181M | $166M | $222M | $206M | $129M | $123M | |
| Operating Income | $-49M | $-197M | $-172M | $-101M | $-87M | $-48M | $141M | $-103M | $-131M | $-127M | $1M | $-100M | |
| Interest Expense | · | · | · | $3M | $802.0K | $15M | $21M | $21M | $7M | $7M | $7M | $2M | |
| Other Non-op | $7M | $12M | $8M | $2M | $134.0K | $3M | $3M | $4M | $2M | $2M | $572.0K | $2M | |
| Pretax Income | · | · | · | · | $-88M | $-59M | $124M | $-121M | $-136M | $-131M | $-5M | $-100M | |
| Income Tax | · | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $-70.0K | |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | · | · | · | |
| Shares (Basic) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | 110,841,000 | 116,747,000 | 105,830,000 | 105,237,000 | · | · | · | |
| EBITDA | $-48M | $-197M | $-171M | $-100M | $-87M | $-45M | $145M | $-100M | $-133M | $-135M | · | $-98M |
Balanço Patrimonial 30
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $67M | $22M | $46M | $64M | $126M | $36M | $80M | $62M | $47M | $203M | $137M | |
| Short-term Investments | $62M | $171M | $148M | $92M | $23M | $26M | $236M | $80M | $249M | $300M | $318M | $202M | |
| Receivables | $2M | $3M | $1M | $28.0K | $14.0K | $395.0K | $57M | $6M | $5M | $7M | $911.0K | $1M | |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | · | $0 | $4M | $5M | $2M | $0 | · | · | |
| Other Current Assets | $3M | $5M | $5M | $2M | $2M | $5M | $5M | $3M | $4M | $4M | $10M | $5M | |
| Current Assets | $102M | $246M | $177M | $141M | $89M | $158M | $338M | $173M | $322M | $358M | $532M | $369M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $1M | $295.0K | $14M | $16M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $5M | $5M | $7M | $6M | $6M | $6M | $76M | $76M | $76M | $79M | $81M | $37M | |
| Accum. Depreciation | $3M | $2M | $5M | $4M | $5M | $6M | $62M | $60M | $59M | $60M | $59M | $36M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | |
| Intangibles | · | · | · | · | · | · | $20M | $50M | $52M | $53M | $53M | $53M | |
| Other Non-current Assets | $368.0K | $368.0K | $828.0K | $412.0K | $2M | $1M | $2M | $285.0K | $429.0K | $461.0K | $433.0K | $3M | |
| Total Assets | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Accounts Payable | $3M | $15M | $14M | $10M | $9M | $5M | $12M | $12M | $39M | $53M | $20M | $13M | |
| Accrued Liabilities | $13M | $30M | $17M | $13M | $13M | $30M | $42M | $21M | $12M | $32M | $25M | $10M | |
| Current Liabilities | $21M | $45M | $32M | $23M | $22M | $47M | $65M | $37M | $105M | $165M | $123M | $45M | |
| Capital Leases | $7M | $5M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $6M | $6M | $19M | $19M | $19M | |
| Other Non-current Liabilities | $7M | $7M | $5M | $5M | $1M | $611.0K | $1M | $238.0K | $292.0K | $805.0K | $14M | $24M | |
| Total Liabilities | $77M | $152M | $136M | $77M | $23M | $47M | $301M | $311M | $368M | $318M | $366M | $187M | |
| Long-term Debt | $54M | $100M | · | $49M | $0 | $12M | $249M | $250M | $252M | $101M | $106M | $108M | |
| Total Debt | $54M | $100M | $100M | · | $0 | $12M | $245M | $245M | $246M | $101M | · | $108M | |
| Common Stock | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K | $142.0K | $106.0K | $106.0K | $106.0K | $105.0K | $104.0K | $104.0K | |
| Paid-in Capital | $2.13B | $2.12B | $1.86B | $1.71B | $1.61B | $1.56B | $1.46B | $1.45B | $1.44B | $1.41B | $1.40B | $1.39B | |
| Retained Earnings | $-2.02B | $-1.97B | $-1.77B | $-1.59B | $-1.49B | $-1.40B | $-1.34B | $-1.47B | $-1.37B | $-1.25B | $-1.11B | $-1.10B | |
| Treasury Stock | $5M | $5M | $3M | $2M | $8M | $5M | $4M | $3M | $2M | $3M | $3M | $2M | |
| AOCI | $30.0K | $119.0K | $31.0K | $-428.0K | $-10.0K | $-6.0K | $84.0K | $-12.0K | $-222.0K | $-195.0K | $-219.0K | $-63.0K | |
| Stockholders' Equity | $108M | $146M | $93M | $117M | $114M | $156M | $117M | $-26M | $68M | $168M | $286M | $284M | |
| Liabilities + Equity | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Shares Outstanding | 365,848,216 | 363,020,303 | · | 189,214,000 | 150,082,000 | 142,289,000 | 106,679,000 | 106,162,000 | 105,711,000 | 104,582,000 | 103,860,000 | 103,663,000 |
Fluxo de Caixa 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $3M | $4M | $4M | $3M | $2M | $727.0K | $2M | |
| Stock-based Comp | $13M | $13M | $14M | $12M | $11M | $13M | $14M | $12M | $9M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | $0 | $0 | $0 | $-6M | $0 | $-13M | $0 | $0 | $-70.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $2M | $2M | · | · | · | |
| Other Non-cash | $-31M | $8M | $328.0K | $1M | $-10M | $-101M | $-28M | $-43M | $-57M | $-44M | · | $16M | |
| Operating Cash Flow | $-68M | $-179M | $-162M | $-89M | $-87M | $-143M | $114M | $-149M | $-185M | $-176M | $185M | $-76M | |
| CapEx | $0 | $1M | $470.0K | $1M | $1M | $87.0K | $70.0K | $95.0K | $228.0K | $231.0K | $910.0K | $80.0K | |
| Investing Cash Flow | $113M | $-15M | $-50M | $-71M | $2M | $381M | $-156M | $170M | $51M | $18M | $-117M | $-108M | |
| Debt Issued | $0 | $0 | $50M | $49M | · | $0 | $0 | $13M | $146M | $0 | $0 | $84M | |
| Net Debt Issued | $0 | $0 | · | $49M | $-12M | $-217M | $-1M | $-2M | $144M | $-2M | · | $82M | |
| Stock Issued | $0 | $0 | $139M | $94M | $37M | $70M | $0 | $732.0K | $8M | $4M | $114.0K | $202M | |
| Stock Repurchased | · | $2M | $824.0K | $864.0K | $3M | $1M | $941.0K | $972.0K | $2M | $621.0K | $357.0K | $887.0K | |
| Net Stock Activity | $0 | $-2M | $138M | $93M | $34M | $69M | $-941.0K | $-240.0K | $6M | $3M | · | $201M | |
| Financing Cash Flow | $-48M | $238M | $188M | $142M | $23M | $-148M | $-2M | $-2M | $150M | $987.0K | $-2M | $284M | |
| Net Change in Cash | $-3M | $44M | $-24M | $-18M | $-62M | $90M | $-44M | $19M | $15M | $-156M | $66M | $100M | |
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M | $-143M | $114M | $-149M | $-186M | $-176M | · | $-76M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-182M | · | $-78M |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% | · | -439.2% | |
| Net Margin | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% | · | -438.8% | |
| Pretax Margin | · | · | · | · | -29449.0% | -244.1% | 38.5% | -190.7% | -156.9% | -169.7% | · | -439.1% | |
| EBITDA Margin | -97.0% | -632.5% | -14218.9% | -72182.0% | -29126.9% | -187.0% | 45.1% | -157.6% | -147.5% | -162.1% | · | -430.7% | |
| ROA | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.9% | 37.1% | -33.5% | -28.3% | -25.1% | · | -26.9% | |
| ROE | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 287.0% | -576.0% | -117.5% | -63.8% | · | -44.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | -53.0% | · | -25.6% |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 | 3.4 | 5.2 | 4.7 | 2.6 | 2.2 | · | 8.2 | |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 | 3.3 | 5.0 | 4.5 | 2.5 | 2.2 | · | 7.6 | |
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 | 0.1 | 2.1 | -9.3 | 4.7 | 0.6 | · | 0.4 | |
| LT Debt / Equity | 0.5 | 0.7 | 1.1 | · | · | 0.0 | 2.0 | -9.2 | 4.4 | 0.5 | · | 0.3 | |
| Interest Coverage | · | · | · | -36.2 | -108.6 | -3.3 | 6.8 | -5.0 | -19.6 | -20.9 | · | -44.5 |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.1 | 2.0 | 0.4 | · | · | 0.9 | 0.7 | 0.8 | 1.9 | · | · | · | |
| Receivables Turnover | 17.0 | 13.9 | 2.3 | 6.6 | 1.5 | 0.8 | 10.3 | 11.8 | 14.7 | 19.8 | · | 25.0 |
Taxas de Crescimento 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.2% | 2481.5% | 766.2% | -53.4% | -98.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 610.2% | 370.7% | -63.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Net Income TTM | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| Market Cap | $421M | · | · | $361M | $591M | $487M | $443M | $705M | $1.04B | $1.45B | · | $4.62B | |
| Enterprise Value | $378M | · | · | · | $505M | $346M | $416M | $790M | $979M | $1.20B | · | $4.39B | |
| P/E | -8.2 | -1.2 | -1.9 | -3.1 | -6.6 | -6.5 | 3.6 | -5.8 | -8.4 | -115.2 | -110.9 | · | |
| P/S | 8.4 | · | · | 2600.0 | 1984.3 | 20.3 | 1.4 | 11.2 | 11.4 | 18.2 | · | 202.3 | |
| P/B | 3.9 | · | · | 3.1 | 5.2 | 3.1 | 3.8 | -26.7 | 20.0 | 9.2 | · | 16.3 | |
| P / Tangible Book | 6.7 | · | · | 5.0 | 8.6 | 4.4 | · | · | · | · | · | · | |
| P / Cash Flow | -6.2 | · | · | -4.1 | -6.8 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| P / FCF | -6.2 | · | · | -4.0 | -6.7 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| EV / EBITDA | -7.8 | · | · | · | -5.8 | -7.7 | 2.9 | -7.9 | -7.3 | -8.9 | · | -44.6 | |
| EV / FCF | -5.6 | · | · | · | -5.7 | -2.4 | 3.7 | -5.3 | -5.3 | -6.8 | · | -58.0 | |
| EV / Revenue | 7.6 | · | · | · | 1693.2 | 14.4 | 1.3 | 12.5 | 10.7 | 15.2 | · | 192.1 | |
| Earnings Yield | -12.2% | -85.1% | -52.3% | -32.5% | -15.2% | -15.5% | 28.0% | -17.2% | -11.8% | -0.87% | -0.90% | · |
Demonstração de Resultados 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21M | $5M | $14M | $29M | $1M | $27M | $2M | $2M | $1M | $701.0K | $162.0K | $317.0K | $24.0K | $28.0K | $39.0K | |
| Cost of Revenue | $39.0K | $108.0K | $201.0K | $10.0K | $33.0K | $30.0K | $348.0K | $71.0K | $166.0K | $31.0K | $70.0K | $7.0K | $8.0K | $0 | $0 | $0 | |
| R&D Expense | $17M | $13M | $11M | $19M | $16M | $15M | $27M | $26M | $18M | $14M | $15M | $18M | $15M | $12M | $14M | $11M | |
| SG&A Expense | $10M | $9M | $9M | $8M | $9M | $12M | $32M | $40M | $39M | $32M | $33M | $32M | $30M | $19M | $16M | $13M | |
| Operating Expenses | $27M | $22M | $20M | $26M | $25M | $27M | $59M | $65M | $57M | $46M | $47M | $50M | $45M | $31M | $30M | $23M | |
| Operating Income | $-27M | $-996.0K | $-15M | $-12M | $4M | $-26M | $-33M | $-64M | $-55M | $-45M | $-47M | $-50M | $-44M | $-31M | $-30M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $4M | $2M | $2M | · | $864.0K | |
| Other Non-op | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $2M | $3M | $1M | $1M | $887.0K | $572.0K | |
| Net Income | $-32M | $-1M | $-16M | $-13M | $3M | $-25M | $-34M | $-65M | $-53M | $-48M | $-50M | $-51M | $-45M | $-32M | $-30M | $-23M | |
| EPS (Basic) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| EPS (Diluted) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| Shares (Basic) | 437,653,000 | 400,240,000 | -725,713,000 | 363,399,000 | 363,294,000 | 362,073,000 | -597,687,000 | 361,492,000 | 310,836,000 | 245,390,000 | -417,592,000 | 244,925,000 | 204,783,000 | 189,014,000 | -307,937,000 | 174,904,000 | |
| Shares (Diluted) | 437,653,000 | 400,240,000 | -725,989,000 | 363,399,000 | 363,570,000 | 362,073,000 | -597,687,000 | 361,492,000 | 310,836,000 | 245,390,000 | -417,592,000 | 244,925,000 | 204,783,000 | 189,014,000 | 7,749,000 | 174,904,000 | |
| EBITDA | $-27M | $-886.0K | · | $-12M | $4M | $-26M | · | $-64M | $-55M | $-45M | · | $-50M | $-44M | $-31M | · | $-23M |
Balanço Patrimonial 28
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M | $36M | $96M | · | $21M | $102M | $26M | · | $19M | |
| Short-term Investments | $150M | $133M | $62M | $66M | $118M | $132M | $171M | $224M | $274M | $259M | · | $197M | $154M | $80M | · | $117M | |
| Receivables | $2M | $12M | $2M | $2M | $2M | $47M | $3M | $3M | $3M | $2M | · | $318.0K | $685.0K | $261.0K | · | $39.0K | |
| Inventory | $1M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K | $585.0K | $514.0K | · | $336.0K | $172.0K | · | · | · | |
| Other Current Assets | $3M | $3M | $3M | $4M | $4M | $3M | $5M | $7M | $8M | $7M | · | $4M | $6M | $3M | · | $3M | |
| Current Assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M | $321M | $365M | · | $223M | $264M | $110M | · | $139M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $932.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $5M | · | $4M | $4M | $4M | · | $5M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | · | $45M | $45M | $45M | · | $45M | |
| Other Non-current Assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K | $828.0K | $828.0K | · | $743.0K | $6M | $6M | · | $7M | |
| Total Assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Accounts Payable | $2M | $3M | $3M | $4M | $6M | $11M | $15M | $14M | $12M | $8M | · | $12M | $11M | $10M | · | $9M | |
| Accrued Liabilities | $12M | $7M | $13M | $14M | $11M | $13M | $30M | $22M | $16M | $15M | · | $20M | $16M | $10M | · | $9M | |
| Current Liabilities | $15M | $10M | $21M | $22M | $35M | $111M | $45M | $36M | $28M | $23M | · | $32M | $26M | $20M | · | $18M | |
| Capital Leases | $6M | $6M | $7M | $7M | $4M | $4M | $5M | $5M | $5M | $5M | · | $5M | · | · | · | · | |
| Other Non-current Liabilities | $9M | $6M | $7M | $8M | $5M | $5M | $7M | $7M | $6M | · | · | · | $5M | $5M | · | $5M | |
| Total Liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M | $133M | $128M | · | $137M | $130M | $75M | · | $48M | |
| Long-term Debt | $51M | $50M | $54M | · | · | $101M | $100M | · | · | · | · | $99M | $99M | $49M | · | $24M | |
| Total Debt | $51M | $50M | · | $57M | $56M | $101M | · | $100M | $99M | $100M | · | $99M | $99M | $49M | · | $24M | |
| Common Stock | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K | $363.0K | $248.0K | · | $245.0K | $245.0K | $190.0K | · | $189.0K | |
| Paid-in Capital | $2.23B | $2.22B | $2.13B | $2.13B | $2.12B | $2.12B | $2.12B | $2.12B | $2.11B | $2.11B | · | $1.86B | $1.86B | $1.71B | · | $1.71B | |
| Retained Earnings | $-2.05B | $-2.02B | $-2.02B | $-2.00B | $-1.99B | $-1.99B | $-1.97B | $-1.93B | $-1.87B | $-1.82B | · | $-1.72B | $-1.67B | $-1.62B | · | $-1.56B | |
| Treasury Stock | $3M | $3M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $3M | $3M | $3M | · | $2M | |
| AOCI | $-204.0K | $-130.0K | $30.0K | $29.0K | $-14.0K | $25.0K | $119.0K | $349.0K | $-193.0K | $-50.0K | · | $-113.0K | $-100.0K | $-163.0K | · | $-491.0K | |
| Stockholders' Equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M | $240M | $289M | · | $140M | $186M | $88M | · | $144M | |
| Liabilities + Equity | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Shares Outstanding | 446,870,629 | 425,708,402 | 365,848,216 | 365,780,799 | · | · | 363,020,303 | · | · | · | · | · | · | · | · | · |
Fluxo de Caixa 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K | $139.0K | $144.0K | $147.0K | $151.0K | $144.0K | $112.0K | $103.0K | $108.0K | |
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-17M | · | · | · | $-22M | · | · | · | $-11M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-17M | $-24M | $17M | $-44M | $-21M | $-54M | $-49M | $-55M | $-51M | $-42M | $-38M | $-32M | $-22M | $-19M | |
| CapEx | · | · | $0 | $0 | · | · | $474.0K | $307.0K | $250.0K | $0 | $0 | $83.0K | $139.0K | $248.0K | $1M | $4.0K | |
| Investing Cash Flow | $-16M | $-70M | $5M | $52M | $15M | $41M | $54M | $53M | $-12M | $-110M | $52M | $-39M | $-75M | $12M | $24M | $-77M | |
| Debt Issued | · | · | · | · | · | · | $0 | $0 | · | · | $-1.0K | $1.0K | $50M | $0 | $25M | $-249.0K | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | $791.0K | $70M | · | · | $0 | $0 | $0 | $0 | $-88.0K | $88.0K | $0 | $-211.0K | $139M | $0 | $-63.0K | $94M | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $2M | · | $0 | $0 | $824.0K | $0 | $0 | |
| Net Stock Activity | · | $70M | · | · | · | · | · | · | · | $-2M | · | · | · | $-824.0K | · | · | |
| Financing Cash Flow | $-512.0K | $89M | $-3M | $0 | $-45M | $-572.0K | $-104.0K | $-916.0K | $-14.0K | $239M | $-1.0K | $-210.0K | $189M | $-824.0K | $25M | $94M | |
| Net Change in Cash | $-26M | $4M | $-15M | $28M | $-13M | $-4M | $32M | $-1M | $-61M | $74M | $1M | $-81M | $76M | $-20M | $28M | $-3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-55M | · | · | · | $-32M | · | · |
Lucratividade 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3835.3% | -4.7% | · | -85.9% | 12.9% | -2034.8% | · | -3639.6% | -3360.9% | -4011.8% | · | -30636.4% | -13955.8% | · | · | · | |
| Net Margin | -4591.8% | -4.9% | · | -90.0% | 11.3% | -2004.4% | · | -3703.5% | -3244.0% | -4282.9% | · | -31188.3% | -14165.3% | · | · | · | |
| EBITDA Margin | -3835.3% | -4.2% | · | -85.9% | 12.9% | -2020.8% | · | -3639.6% | -3360.9% | -3999.0% | · | -30636.4% | -13955.8% | · | · | · | |
| ROA | -13.4% | -0.37% | · | -4.9% | 1.1% | -7.1% | · | -21.7% | -15.5% | -16.7% | · | -21.6% | -20.9% | -21.4% | · | -12.8% | |
| ROE | -20.9% | -0.64% | · | -8.6% | 1.8% | -12.3% | · | -40.8% | -25.1% | -25.7% | · | -35.6% | -34.9% | -35.3% | · | -16.7% |
Liquidez e Solvência 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 18.8 | · | 5.6 | 4.2 | 2.2 | · | 7.5 | 11.5 | 15.6 | · | 6.9 | 10.1 | 5.4 | · | 7.5 | |
| Quick Ratio | 13.1 | 18.4 | · | 5.4 | 4.1 | 2.2 | · | 7.2 | 11.2 | 15.3 | · | 6.8 | 9.9 | 5.2 | · | 7.4 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | 0.8 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.5 | 0.6 | · | 0.2 | |
| LT Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | 0.5 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.5 | 0.6 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -12.7 | -22.6 | -17.1 | · | -26.7 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Inventory Turnover | 0.1 | 0.5 | · | 0.0 | 0.1 | 0.1 | · | 0.1 | 0.4 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Receivables Turnover | 0.4 | 0.7 | · | 5.4 | 12.0 | 0.1 | · | 1.1 | 1.0 | 1.3 | · | 0.9 | 0.9 | · | · | · |
Avaliação (TTM) 12
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $65M | $65M | · | $46M | $34M | $6M | · | $5M | $3M | $2M | · | $542.0K | $415.0K | · | · | · | |
| Net Income TTM | $-42M | $-36M | · | $-100M | $-140M | $-192M | · | $-217M | $-197M | $-176M | · | $-151M | $-125M | $-103M | · | $-95M | |
| Market Cap | $1.07B | $664M | · | $494M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $933M | $543M | · | $434M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -24.0 | -15.6 | · | -4.8 | -2.3 | -0.7 | · | -2.1 | -2.1 | -3.0 | · | -1.5 | · | · | · | · | |
| P/S | 16.5 | 10.2 | · | 10.7 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 6.1 | 3.3 | · | 4.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 8.3 | 4.2 | · | 6.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -45.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -35.2 | -613.0 | · | -35.6 | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 14.4 | 8.3 | · | 9.4 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -4.2% | -6.4% | · | -20.7% | -43.2% | -134.8% | · | -48.4% | -47.6% | -33.3% | · | -67.0% | · | · | · | · |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $50M | $31M | $1M | $139.0K | $298.0K |
| Margem Operacional % | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% |
| Lucro líquido | $-50M | $-200M | $-177M | $-102M | $-88M |
| EPS Diluído | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.5 | 0.7 | 1.1 | — | 0.0 |
| Índice de liquidez corrente | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 |
| Índice de Liquidez Seca | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-68M | $-180M | $-162M | $-90M | $-88M |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 169 declarantes · $760.9M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 48 (+14 vs trimestre anterior) | 27 (+14 vs trimestre anterior) | 34 (-11 vs trimestre anterior) | 37 (+17 vs trimestre anterior) | +25.0M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| Artal Group S.A. | $420.374.549 | 175.156.062 | 55,25% | Ações |
| Siren, L.L.C. | $106.328.443 | 44.303.518 | 13,97% | Ações |
| FMR LLC | $65.057.059 | 27.107.108 | 8,55% | Ações |
| Sessa Capital IM, L.P. | $45.506.006 | 18.960.836 | 5,98% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.762.899 | 9.901.208 | 3,12% | Ações |
| Point72 Asset Management, L.P. | $19.803.180 | 8.251.325 | 2,60% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $12.946.507 | 5.393.025 | 1,70% | Ações |
| STATE STREET CORP | $11.802.646 | 4.917.769 | 1,55% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5.658.598 | 2.357.749 | 0,74% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4.696.260 | 1.956.775 | 0,62% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $3.922.970 | 1.634.571 | 0,52% | Ações |
| CIBC Private Wealth Group LLC | $3.240.347 | 2.400.257 | 0,43% | Ações |
| Ishara Investments LP | $3.050.400 | 1.271.000 | 0,40% | Ações |
| MILLENNIUM MANAGEMENT LLC | $2.722.150 | 1.134.229 | 0,36% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $2.704.800 | 1.127.000 | 0,36% | Ações |
| MACKENZIE FINANCIAL CORP | $2.312.050 | 963.354 | 0,30% | Ações |
| ADAR1 Capital Management, LLC | $1.800.000 | 750.000 | 0,24% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.604.400 | 668.500 | 0,21% | Opção de compra |
| TWO SIGMA INVESTMENTS, LP | $1.544.266 | 643.444 | 0,20% | Ações |
| JANE STREET GROUP, LLC | $1.398.960 | 582.900 | 0,18% | Opção de compra |
| CITADEL ADVISORS LLC | $1.348.733 | 561.972 | 0,18% | Ações |
| VANGUARD GROUP INC | $1.277.587 | 1.110.945 | 0,17% | Ações |
| Compagnie Lombard Odier SCmA | $1.152.000 | 480.000 | 0,15% | Ações |
| BARCLAYS PLC | $890.636 | 371.098 | 0,12% | Ações |
| CITADEL ADVISORS LLC | $886.320 | 369.300 | 0,12% | Opção de compra |
| XTX Topco Ltd | $858.905 | 357.877 | 0,11% | Ações |
| GOLDMAN SACHS GROUP INC | $725.810 | 302.421 | 0,10% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $618.960 | 257.900 | 0,08% | Ações |
| RHUMBLINE ADVISERS | $616.523 | 256.885 | 0,08% | Ações |
| WELLS FARGO & COMPANY/MN | $544.865 | 227.027 | 0,07% | Ações |
| GROUP ONE TRADING LLC | $420.031 | 175.013 | 0,06% | Ações |
| Virtus Investment Advisers, LLC | $408.996 | 170.415 | 0,05% | Ações |
| Headlands Technologies LLC | $401.275 | 167.198 | 0,05% | Ações |
| Ikarian Capital, LLC | $395.218 | 164.674 | 0,05% | Ações |
| CITIGROUP INC | $386.021 | 160.842 | 0,05% | Ações |
| Quarry LP | $374.846 | 156.186 | 0,05% | Ações |
| MetLife Investment Management, LLC | $351.384 | 146.410 | 0,05% | Ações |
| Bank of New York Mellon Corp | $345.307 | 143.878 | 0,05% | Ações |
| BANK OF AMERICA CORP /DE/ | $344.321 | 143.467 | 0,05% | Ações |
| PANAGORA ASSET MANAGEMENT INC | $316.901 | 132.042 | 0,04% | Ações |
| State of Wyoming | $285.816 | 119.090 | 0,04% | Ações |
| BlackRock, Inc. | $284.436 | 118.515 | 0,04% | Ações |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $273.874 | 114.114 | 0,04% | Ações |
| Cornerstone Investment Partners, LLC | $272.974 | 113.739 | 0,04% | Ações |
| Invesco Ltd. | $238.190 | 99.246 | 0,03% | Ações |
| ALGERT GLOBAL LLC | $221.160 | 92.150 | 0,03% | Ações |
| TWO SIGMA ADVISERS, LP | $208.124 | 180.977 | 0,03% | Ações |
| BANK OF NOVA SCOTIA | $207.857 | 86.607 | 0,03% | Ações |
| LPL Financial LLC | $203.799 | 84.916 | 0,03% | Ações |
| Vanguard Global Advisers, LLC | $187.070 | 77.946 | 0,02% | Ações |
| AQR CAPITAL MANAGEMENT LLC | $180.101 | 75.042 | 0,02% | Ações |
| Police & Firemen's Retirement System of New Jersey | $176.165 | 73.402 | 0,02% | Ações |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | $171.426 | 71.427 | 0,02% | Ações |
| PRUDENTIAL FINANCIAL INC | $171.228 | 71.345 | 0,02% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $167.393 | 69.747 | 0,02% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $164.160 | 68.400 | 0,02% | Ações |
| TWO SIGMA SECURITIES, LLC | $159.300 | 66.375 | 0,02% | Ações |
| SEI INVESTMENTS CO | $153.449 | 63.937 | 0,02% | Ações |
| Nuveen, LLC | $153.449 | 63.937 | 0,02% | Ações |
| Straight Path Wealth Management | $150.398 | 62.666 | 0,02% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $144.000 | 60.000 | 0,02% | Ações |
| R Squared Ltd | $131.964 | 54.985 | 0,02% | Ações |
| Vanguard Personalized Indexing Management, LLC | $130.402 | 54.334 | 0,02% | Ações |
| Fortis Group Advisors, LLC | $120.000 | 50.000 | 0,02% | Ações |
| Schonfeld Strategic Advisors LLC | $118.642 | 49.435 | 0,02% | Ações |
| SCOTIA CAPITAL INC. | $117.291 | 48.871 | 0,02% | Ações |
| PROFUND ADVISORS LLC | $116.606 | 48.586 | 0,02% | Ações |
| VOYA INVESTMENT MANAGEMENT LLC | $114.650 | 47.771 | 0,02% | Ações |
| AXQ CAPITAL, LP | $109.745 | 45.727 | 0,01% | Ações |
| BOOTHBAY FUND MANAGEMENT, LLC | $106.356 | 44.315 | 0,01% | Ações |
| ALLIANCEBERNSTEIN L.P. | $105.768 | 67.800 | 0,01% | Ações |
| WINTON GROUP Ltd | $103.680 | 43.200 | 0,01% | Ações |
| INTECH INVESTMENT MANAGEMENT LLC | $101.978 | 42.491 | 0,01% | Ações |
| LMR Partners LLP | $98.618 | 41.091 | 0,01% | Ações |
| BANK OF MONTREAL /CAN/ | $96.000 | 40.000 | 0,01% | Ações |
| NORTHERN TRUST CORP | $93.794 | 39.081 | 0,01% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $90.672 | 37.780 | 0,01% | Ações |
| Cubist Systematic Strategies, LLC | $85.704 | 63.484 | 0,01% | Ações |
| Rafferty Asset Management, LLC | $81.816 | 34.090 | 0,01% | Ações |
| ProShare Advisors LLC | $78.212 | 32.588 | 0,01% | Ações |
| Leonteq Securities AG | $72.000 | 30.000 | 0,01% | Ações |
| PINNACLE ASSOCIATES LTD | $69.636 | 29.015 | 0,01% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $58.135 | 24.223 | 0,01% | Ações |
| Legal & General Group Plc | $58.044 | 24.185 | 0,01% | Ações |
| XPONANCE LLC | $57.031 | 23.763 | 0,01% | Ações |
| Graham Capital Management, L.P. | $56.498 | 23.541 | 0,01% | Ações |
| D. E. Shaw & Co., Inc. | $53.280 | 22.200 | 0,01% | Ações |
| Quadrature Capital Ltd | $52.795 | 21.998 | 0,01% | Ações |
| Invera Wealth Advisors, LLC | $48.000 | 20.000 | 0,01% | Ações |
| DIKER MANAGEMENT LLC | $48.000 | 20.000 | 0,01% | Ações |
| TIAA-CREF INDIVIDUAL & INSTITUTIONAL SERVICES, LLC | $48.000 | 20.000 | 0,01% | Ações |
| Russell Investments Group, Ltd. | $47.764 | 19.902 | 0,01% | Ações |
| Point72 Asia (Singapore) Pte. Ltd. | $47.282 | 35.024 | 0,01% | Ações |
| Tower Research Capital LLC (TRC) | $46.764 | 19.485 | 0,01% | Ações |
| KWB Wealth | $46.736 | 40.640 | 0,01% | Ações |
| SBI Securities Co., Ltd. | $46.092 | 19.205 | 0,01% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $45.682 | 19.034 | 0,01% | Ações |
| CREDIT AGRICOLE S A | $45.540 | 18.975 | 0,01% | Ações |
| WOLVERINE TRADING, LLC | $43.785 | 31.500 | 0,01% | Opção de venda |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $42.960 | 17.900 | 0,01% | Opção de venda |
Executivos da empresa 49 insiders · 32 diretores · 19 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Michael Exton | Chief Executive Officer | 28 de Fevereiro de 2026 M | 298.432 | 0 | 0 | $0 |
| Lonnel Coats | Chief Executive Officer | 28 de Fevereiro de 2024 M | 1.098.068 | 0 | 0 | $0 |
| Arthur T Sands | President & CEO | 28 de Fevereiro de 2014 M | 1.021.329 | 0 | 0 | $0 |
| Scott M Coiante | SVP, Chief Financial Officer | 28 de Fevereiro de 2026 M | 105.356 | 0 | 0 | $0 |
| Ajay Bansal | EVP Corp Dev and CFO | 2 de Junho de 2009 A | — | 0 | 0 | $0 |
| Julia P Gregory | EVP and CFO | 7 de Fevereiro de 2008 A | 50.200 | 0 | 0 | $0 |
| Jeffrey L Wade | President and COO | 8 de Julho de 2024 A | 324.214 | 0 | 0 | $0 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 28 de Fevereiro de 2026 M | 31.264 | 0 | 0 | $0 |
| Suma Gopinathan | SVP, Discovery | 28 de Fevereiro de 2026 M | 150.132 | 0 | 0 | $0 |
| Wendy Mcdermott | SVP, Human Resources | 28 de Fevereiro de 2026 M | 277.945 | 0 | 0 | $0 |
| Craig B Granowitz | SVP, Chief Medical Officer | 28 de Fevereiro de 2026 M | 323.430 | 0 | 0 | $0 |
| Lisa Defrancesco | SVP, IR and Corp Comm | 28 de Fevereiro de 2026 M | 93.869 | 0 | 0 | $0 |
| Brian T Crum | SVP, General Counsel & Secr. | 28 de Fevereiro de 2026 M | 428.802 | 0 | 0 | $0 |
| Kristen Alexander | VP, Finance and Accounting | 28 de Fevereiro de 2025 M | 76.368 | 0 | 0 | $0 |
| Alan J Main | EVP, Innov & Chem Sciences | 28 de Fevereiro de 2025 M | 339.104 | 0 | 0 | $0 |
| Brian Corrigan | SVP, Regulatory & QA | 13 de Fevereiro de 2025 A | — | 0 | 0 | $0 |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | 28 de Fevereiro de 2024 M | 162.672 | 0 | 0 | $0 |
| Thomas Garner | SVP, Chief Commercial Officer | 8 de Fevereiro de 2024 A | — | 0 | 0 | $0 |
| Kiernan Seth | VP, Chief Commercial Officer | 28 de Fevereiro de 2023 M | 53.136 | 0 | 0 | $0 |
| James F Tessmer | VP, Finance & Accounting | 15 de Março de 2021 M | 71.766 | 0 | 0 | $0 |
| Alexander A Santini | EVP and CCO | 22 de Abril de 2020 F | 55.584 | 0 | 0 | $0 |
| Pablo Lapuerta | EVP and CMO | 22 de Abril de 2020 F | 85.719 | 0 | 0 | $0 |
| John Northcott | VP, Marketing, Comm Strategy | 2 de Março de 2015 M | 8.235 | 0 | 0 | $0 |
| Brian P Zambrowicz | EVP, Chief Scientific Officer | 28 de Fevereiro de 2014 M | 278.703 | 0 | 0 | $0 |
| Steven Alan Tragash | VP, Corporate Affairs | 15 de Fevereiro de 2010 A | — | 0 | 0 | $0 |
| Philip M Brown | SVP, Clinical Development | 15 de Fevereiro de 2010 A | 27.306 | 0 | 0 | $0 |
| James R Piggott PHD | SVP of Pharm Bio | 7 de Fevereiro de 2008 A | 0 | 0 | 0 | $0 |
| Lance K Ishimoto | SVP, Intellectual Property | 7 de Fevereiro de 2008 A | 10.200 | 0 | 0 | $0 |
| Tamar D Howson | EVP of Bus Dev | 7 de Fevereiro de 2008 A | — | 0 | 0 | $0 |
| Walter F Colbert | SVP, HR and Corp Serv | 13 de Fevereiro de 2007 A | — | 0 | 0 | $0 |
| Randall B Riggs | SVP, Corp Licensing | 23 de Fevereiro de 2004 M | 15.000 | 0 | 0 | $0 |
| Christophe Person | VP Informatics | 12 de Janeiro de 2004 M | 0 | 0 | 0 | $0 |
| Ivan Cheung | Conselheiro | 3 de Junho de 2026 M | 89.312 | 0 | 0 | $0 |
| Diane E. Sullivan | Conselheiro | 3 de Junho de 2026 M | 126.122 | 0 | 0 | $0 |
| Judith L Swain | Conselheiro | 3 de Junho de 2026 M | 174.486 | 0 | 0 | $0 |
| Amouyal Philippe | Conselheiro | 3 de Junho de 2026 M | 374.486 | 0 | 0 | $0 |
| Sam L Barker | Conselheiro | 3 de Junho de 2026 M | 213.771 | 0 | 0 | $0 |
| Christopher J Sobecki | Conselheiro | 3 de Junho de 2026 M | 293.177 | 0 | 0 | $0 |
| Raymond Debbane | Conselheiro | 3 de Junho de 2026 M | 1.995.498 | 7 | 0 | $723.048 |
| Robert J Lefkowitz MD | Conselheiro | 13 de Maio de 2024 A | 48.364 | 0 | 0 | $0 |
| Frank Palantoni | Conselheiro | 21 de Maio de 2023 M | 40.332 | 0 | 0 | $0 |
| Alan S Nies | Conselheiro | 21 de Maio de 2023 M | 41.046 | 0 | 0 | $0 |
| Invus C.V. | Conselheiro | 31 de Dezembro de 2020 J | 0 | 0 | 0 | $0 |
| Kathleen M Wiltsey | Conselheiro | 24 de Abril de 2009 A | — | 0 | 0 | $0 |
| Clayton Stuart Rose | Conselheiro | 26 de Junho de 2007 P | 25.000 | 0 | 0 | $0 |
| Barry Mills | Conselheiro | 26 de Abril de 2007 A | 25.000 | 0 | 0 | $0 |
| Patricia M Cloherty | Conselheiro | 27 de Abril de 2006 A | — | 0 | 0 | $0 |
| Thomas C Caskey | Conselheiro | 13 de Outubro de 2005 P | 6.300 | 0 | 0 | $0 |
| Praveen Tyle | — | 28 de Fevereiro de 2021 M | 120.791 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 11 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 declarações | 8 de Maio de 2026 | 39,40% | Emenda | — | SEC |
| Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 declarações | 9 de Dezembro de 2024 | — | Declaração inicial | — | SEC |
| 24 de Fevereiro de 2012 | — | Declaração inicial | — | SEC | |
| Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) | 27 de Dezembro de 2011 | — | Declaração inicial | — | SEC |
| 14 de Novembro de 2011 | — | Declaração inicial | — | SEC | |
| 15 de Agosto de 2011 | — | Declaração inicial | — | SEC | |
| Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. | 19 de Março de 2010 | — | Declaração inicial | Estrutura de capital | SEC |
| Estate of Gordon A. Cain (, Mary H. Cain ×4 declarações | 5 de Agosto de 2005 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 8 de Agosto de 2003 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 18 de Julho de 2003 | — | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 19 de Março de 2003 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 14 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 1.032.223 NS | 31 de Maio de 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 110.085 NS | 31 de Maio de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 de Julho de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 de Julho de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 de Julho de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 de Julho de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 de Julho de 2026 | Diário |
| IWV · iShares Trust | — | — | 18 de Agosto de 2026 | Diário |
| IWO · iShares Trust | — | — | 18 de Agosto de 2026 | Diário |
| IWM · iShares Trust | — | — | 18 de Agosto de 2026 | Diário |
| IWC · iShares Trust | — | — | 18 de Agosto de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 13 de Julho de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | — | — | 20 de Julho de 2026 | Diário |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | 5 de Agosto de 2026 | Diário |